High Fructose Diet Fuels Inflammation by Rewiring T Cell Metabolism
New research shows fructose directly programs immune T cells toward inflammatory states via mTORC1 and glutamine metabolism—and metformin reverses it.
Summary
A 2025 study in Signal Transduction and Targeted Therapy reveals that high fructose consumption directly reprograms CD4+ T cells, promoting inflammatory Th1 and Th17 cell generation through mTORC1 activation via glutamine metabolism. Reactive oxygen species (ROS)-driven TGF-β activation also contributes to Th17 expansion. In mouse models, high fructose intake worsened colitis without raising blood glucose or body weight. Crucially, the diabetes drug metformin reversed these effects by suppressing mTORC1 and reducing ROS-mediated TGF-β activation, pointing to a novel therapeutic strategy for diet-induced immune dysregulation.
Detailed Summary
Fructose, consumed globally in vast quantities through sugary beverages and processed foods, has long been linked to metabolic disease. This study breaks new ground by demonstrating that fructose directly reshapes adaptive immunity—specifically CD4+ T cell differentiation—independent of weight gain or hyperglycemia, with significant consequences for inflammatory disease.
Researchers at Sichuan University and NIH fed mice 20% fructose water for two months and found elevated frequencies of IFN-γ+ Th1 and IL-17A+ Th17 cells in the colon, spleen, mesenteric lymph nodes, and liver—without changes in Treg, Th2, or Tr1 populations. High fructose feeding significantly worsened both DSS-induced colitis and CD4+CD25−CD45RBhi T cell transfer-induced colitis, establishing a direct link between dietary fructose and T cell-driven intestinal inflammation.
Mechanistically, the team showed that T cells do not express the primary fructose transporter GLUT5 and cannot directly metabolize fructose. Instead, fructose is converted by intestinal epithelial cells and other tissues into metabolites—including fructose-1-phosphate and downstream intermediates—that indirectly elevate extracellular glutamine availability. This glutamine surplus is taken up by T cells and fuels mTORC1 activation, which in turn drives the transcriptional programs necessary for Th1 and Th17 differentiation. In parallel, fructose exposure elevated intracellular reactive oxygen species (ROS) in T cells, which activated latent TGF-β and further amplified Th17 generation through a distinct pathway.
Metformin, an AMPK-activating drug widely used for type 2 diabetes, potently reversed both mechanisms: it suppressed mTORC1 signaling and reduced ROS-mediated TGF-β activation, thereby normalizing Th1 and Th17 frequencies in vitro and in vivo. In colitis mouse models with high fructose feeding, metformin treatment significantly ameliorated disease severity, intestinal damage, and inflammatory cytokine production, positioning it as a plausible therapeutic agent for diet-induced immune imbalance.
These findings identify a previously unrecognized immunological consequence of high fructose consumption and propose a coherent mechanistic framework—glutamine-mTORC1 and ROS-TGF-β axes—by which a common dietary sugar directly corrupts T cell immune homeostasis. The work also opens the door to repurposing metformin for inflammatory conditions exacerbated by Western dietary patterns.
Key Findings
- High fructose intake elevated Th1 and Th17 cells in colon, spleen, liver, and lymph nodes without raising blood glucose or body weight.
- Fructose promotes Th1/Th17 differentiation by boosting glutamine metabolism, which activates mTORC1 in T cells.
- ROS-induced TGF-β activation provides a second, independent pathway through which fructose drives Th17 generation.
- T cells lack GLUT5 and cannot directly metabolize fructose; the effect is indirect via extracellular metabolite changes.
- Metformin reversed fructose-induced Th1/Th17 expansion and reduced colitis severity in mouse models.
Methodology
Male C57BL/6 mice received 20% fructose water for 2 months; T cell subsets were profiled by flow cytometry across multiple tissues. Colitis was modeled by DSS administration and adoptive CD4+ T cell transfer. In vitro mechanistic studies used T cell differentiation assays with glutamine pathway inhibitors, mTORC1 reporters, ROS measurements, and metformin treatment.
Study Limitations
All mechanistic and in vivo experiments were conducted in mice; human T cell validation is limited. The study does not fully characterize which systemic fructose metabolites reach T cells or quantify their concentrations in physiologically relevant conditions. Long-term effects of high fructose beyond 2 months and dose-response relationships were not explored.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.